Stroke is a serious cerebrovascular event constituting one of the most common causes of long-term disability and death, and a major burden to public health worldwide. According to WHO, stroke is “a clinical syndrome consisting of rapidly developing clinical signs of focal (or global in case of coma) disturbance of cerebral function lasting more than 24 hours or leading to death with no apparent cause other than a vascular origin.”

This report provides the current incident population for stroke across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current incidence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several features of stroke patients, as well as the main types and subtypes of the disease have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities of stroke include:

  • Cardiovascular conditions (mainly cardiac arrhythmias and myocardial infarction)
  • Venous thromboembolism (DVT, pulmonary embolism)
  • Hypertension
  • Diabetes mellitus
  • Pneumonia
  • Urinary tract infections
  • Fractures (due to falls caused by physical disability)
  • Pain
  • Depression

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Ability to quantify patient populations in global stroke market to target the development of future products, pricing strategies and launch plans.
  • Further insight into the incidence of the subdivided types of stroke and identification of patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Better understanding of the impact of specific co-morbid conditions on the incident population of stroke patients.
  • Identification of stroke patient sub-populations that require treatment.
  • Better understanding of the specific markets that have the largest number of stroke patients.